<DOC>
	<DOC>NCT00563368</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.</brief_summary>
	<brief_title>A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>70 years of age or less with body mass index (BMI) between 30 and 45 kg/m2 Informed Consent Females of childbearing potential must be using adequate contraception Stroke/myocardial infarction (MI)/unstable cardiovascular disease within 6 months Clinically significant renal, hepatic or psychiatric disease Unstable thyroid disease or replacement therapy Nephrolithiasis Obesity of known genetic or endocrine origin Participation in a formal weight loss program or lifestyle intervention Glaucoma or elevated intraocular pressure Pregnancy or breastfeeding Drug or Alcohol abuse Smoking cessation within previous 3 months or plans to quit smoking during study Eating disorders within past year Cholelithiasis within past 6 months Type 2 diabetes Previous bariatric surgery Bipolar disorder or psychosis Steroid hormone therapy not stable for 3 months Systolic blood pressure &gt; 160 mmHg, diastolic blood pressure &gt; 100 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>